Fixed Rate Continuous Subcutaneous Glucagon Infusion (CSGI) vs Placebo in Type 1 Diabetes Mellitus Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses to Insulin-Induced Hypoglycemia
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2019
Price : $35 *
At a glance
- Drugs Glucagon (Primary)
- Indications Hypoglycaemia
- Focus Pharmacodynamics
- Sponsors XERIS Pharmaceuticals
- 21 Nov 2019 Results presented in a Xeris Pharmaceuticals media release.
- 07 Nov 2019 According to a Xeris Pharmaceuticals media release, data from the trial is expected by year end 2019.
- 07 Nov 2019 Status changed from recruiting to active, no longer recruiting, according to a Xeris Pharmaceuticals media release.